Psilocybin Microdosing for Mood and Cognition

This trial explores how microdosing psilocybin, a compound found in magic mushrooms, affects mood and thinking over 30 days. Participants will receive either a tiny amount of psilocybin or a placebo. Researchers will compare the results to determine any impact on well-being or brain scans. The trial seeks individuals who have never used psychedelics and are free from current mood or substance use disorders. Those who meet these criteria and wish to explore potential mood enhancements without psychedelic effects may find this trial suitable. As an Early Phase 1 trial, the research focuses on understanding how microdosing psilocybin works in people, offering participants a chance to be among the first to explore its effects.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

Research shows that the safety of psilocybin microdosing is still under investigation. Some studies suggest it can improve mood and help with anxiety and depression. However, other reports mention possible side effects such as trouble sleeping, increased anxiety, and stomach issues.

Most treatments for mood and cognitive conditions, like antidepressants or cognitive therapy, can take weeks to show effectiveness and often work by altering neurotransmitter levels over time. Unlike these standard treatments, psilocybin is unique because it is derived from psychedelic mushrooms and works differently by targeting serotonin receptors in the brain, potentially leading to rapid changes in mood and cognition. Researchers are excited about psilocybin because it can produce noticeable effects much faster than traditional treatments, possibly within days, and might offer benefits with minimal dosing. This new approach could revolutionize how we address mood disorders by providing quicker relief with fewer doses.

Research has shown that small doses of psilocybin might improve mood and mental health. In a large study, participants who took these small doses reported feeling happier and mentally healthier after one month compared to those who did not. Other reports have noted benefits such as better mood, improved understanding and management of emotions, and a greater appreciation for beauty. However, some studies found no noticeable changes in mood or thinking compared to a placebo. In this trial, participants in the psychedelic group will receive an imperceptible dose of psilocybin, while those in the placebo group will receive a placebo. Overall, while results vary, some evidence suggests that psilocybin microdosing could help improve mood and mental health.²³⁴⁶⁷